ASCO 2019 | Patient-reported outcomes with CAR T-cell therapy

Surbhi Sidana

Surbhi Sidana, MD, of the Mayo Clinic, Rochester, MN, talks about patient-reported outcomes (PROs) for patients undergoing CAR T-cell therapy at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

Share this video  
Similar topics
Related videos
Venetoclax monotherapy for relapsed/refractory Waldenström’s macroglobulinemia
Jorge Castillo
Waldenström's PFS unaffected by ibrutinib dose reduction, for now
Jorge Castillo
Anti-CD19 CAR T-cell therapy in combination with ibrutinib for CLL/SLL
Saar Gill
An exciting era for CAR T-cell therapy
Mohamad Mohty
Ibrutinib combinations for CLL: iLLUMINATE results & more
Carol Moreno
Acute Lymphoblastic Leukemia, B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Leukemia, Lymphoma
CAR-T
ASCO 2019
Interview
2nd June 2019
More from Surbhi Sidana
Educating the patient about CAR T-cell therapy
Renal and cardiac involvement in amyloidosis
QoL in patients undergoing CAR T-cell therapy versus transplantation
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals